Tech Company Financing Transactions
Tevogen Bio Funding Round
Tevogen Bio, operating out of Warren, secured $8 million in investment from KRHP.
Transaction Overview
Company Name
Announced On
3/3/2025
Transaction Type
Debt
Amount
$8,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Warren, NJ Undisclosed
USA
Warren, NJ Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ryan Saadi
Browse more venture capital transactions:
Prev: 3/3/2025: Callio Therapeutics venture capital transaction
Next: 3/3/2025: Moonwatt venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs